{"companyId":277564,"requestedLanguage":"ja","resolvedLanguage":"ja","availableLanguages":["en","ja"],"companyName":"バーニングロックバイオテックリミテッド","headOfficeLocation":"北京、中国","presidentName":"ハン・ユシェン","companySummary":null,"stockCode":"BNR","currency":"USD","capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["brbiotech.gcs-web.com"],"businessContents":["次世代シーケンシング（NGS）精密腫瘍学検査","がんのコンパニオン診断と早期発見サービス"],"relations":[],"dataSources":[{"detailNumber":1,"url":"https://brbiotech.gcs-web.com/news-releases/news-release-details/burning-rock-announces-licensing-myriad-mychoicer-tumor-testing","scoreAbout":400,"scoreBusiness":300,"scoreGroup":0,"scoreCustomer":0}]}